Shares of Merck climbed approximately 1% during premarket hours Thursday, reaching $125, following the FDA’s ahead-of-schedule approval of Lipfendra—the inaugural oral PCSK9 inhibitor—under the regulatory body’s accelerated review pathway. Year-to-date in 2026, the stock has advanced roughly 18%.
This regulatory clearance represents a significant achievement for Merck. Marketed as Lipfendra, enlicitide becomes the first tablet formulation capable of blocking PCSK9, a protein responsible for regulating LDL-C—widely recognized as “bad cholesterol.” Previously, PCSK9 blockers existed solely as injectable therapies.
Heart-related illnesses remain the primary mortality driver worldwide and contribute to approximately 25% of fatalities in the United States. While statins have served as the standard treatment approach since the 1980s, they prove inadequate for numerous patients, especially individuals with genetically-driven elevated cholesterol.
Clinical trial data from two studies revealed Lipfendra decreased LDL-C concentrations by 60%. Researchers identified no significant safety concerns, although approximately 7% of participants experienced diarrhea. An extended investigation monitoring cardiovascular events including heart attacks and strokes remains in progress and isn’t scheduled to conclude until 2029.
Merck is launching into a therapeutic space currently dominated by injectable PCSK9 medications. Amgen’s Repatha recorded $900 million in first-quarter 2026 revenue, representing 34% year-over-year growth. Novartis’s Leqvio contributed $400 million during the identical timeframe, marking a 76% increase. Regeneron’s Praluent achieved $260 million in 2025 U.S. sales.
With a monthly list price of $315, Lipfendra offers compelling value compared to injectable alternatives commanding over $500. Merck announced commercial distribution will commence within several weeks.
Wall Street analysts anticipate Lipfendra could surpass $350 million in sales during the coming year, with extended-term revenue potentially hitting $5 billion yearly assuming robust market adoption.
The medication also holds considerable strategic importance. Keytruda, Merck’s dominant oncology franchise producing $32 billion in yearly revenue, faces patent expiration in 2028. Lipfendra represents a key asset in Merck’s portfolio strategy to bridge that impending revenue shortfall.
In related developments, Guggenheim confirmed its Buy stance and $145 valuation target for MRK Thursday, highlighting successful Phase 3 results from collaborator Kelun-Biotech. The study evaluated Kelun’s TROP2-targeting ADC sacituzumab tirumotecan paired with Keytruda in treatment-naive NSCLC patients presenting PD-L1 negative non-squamous disease.
The therapeutic combination delivered substantial progression-free survival benefits and favorable overall survival trends compared to the comparator group. Comprehensive findings are anticipated at the ESMO conference this October.
BMO Capital maintains a $142 valuation on MRK. Scotiabank projects a higher $155 target, supported by an enhanced cash flow multiple in their financial modeling. MRK currently trades close to its 52-week peak of $130.29.
AstraZeneca is simultaneously advancing laroprovstat, a rival oral PCSK9 inhibitor, suggesting Lipfendra’s first-to-market positioning may face competition within a compressed timeframe.
The post Merck (MRK) Stock Climbs After FDA Greenlight for Revolutionary Cholesterol Medication appeared first on Blockonomi.
